hepatocellular-carcinoma

Documents about hepatocellular-carcinoma

• Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial#252994ClinicalTrials.gov
• Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)#848711ClinicalTrials.gov
• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma#903344ClinicalTrials.gov
• Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System#887733ClinicalTrials.gov
• Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial#121347ClinicalTrials.gov
• PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy#184839ClinicalTrials.gov
• Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma#217025ClinicalTrials.gov
• Transcriptomes From Hepatocellular Carcinoma and Normal Liver Tissues#260333Rīga Stradiņš University Institutional Repository Dataverse Dataverse OAI Archive
• Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clinical Trial#279493ClinicalTrials.gov
• Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases#801176ClinicalTrials.gov
• Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma#826510ClinicalTrials.gov
• ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma#835920ClinicalTrials.gov
• Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma#842529ClinicalTrials.gov
• Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)#845509ClinicalTrials.gov
• The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt#854799ClinicalTrials.gov
• Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;#863586ClinicalTrials.gov
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)#871128ClinicalTrials.gov
• Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma#894819ClinicalTrials.gov
• Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma#897707ClinicalTrials.gov
• CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma#899096ClinicalTrials.gov
• Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI#905080ClinicalTrials.gov
• Imjudo & Imfinzi PMS#891365ClinicalTrials.gov
• Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma#154658ClinicalTrials.gov
• Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis#181747ClinicalTrials.gov
• A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma#195399ClinicalTrials.gov
• Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma#245527ClinicalTrials.gov
• HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure#256888ClinicalTrials.gov
• Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study#311130ClinicalTrials.gov
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab#363623ClinicalTrials.gov
• Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer#451469ClinicalTrials.gov
• Driver mutation impact in Chinese hepatocellular carcinoma#483566PLOS
• TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria#828016ClinicalTrials.gov
• Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma#837247ClinicalTrials.gov
• A Study of Anlotinib in Patients With Hepatocellular Carcinoma#837610ClinicalTrials.gov
• Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)#851134ClinicalTrials.gov
• The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients#852767ClinicalTrials.gov
• TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion#854766ClinicalTrials.gov
• IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients#859429ClinicalTrials.gov
• Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma#863744ClinicalTrials.gov
• Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)#873821ClinicalTrials.gov
• Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma#892379ClinicalTrials.gov
• A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma#894469ClinicalTrials.gov
• The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)#895522ClinicalTrials.gov
• The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma#907334ClinicalTrials.gov
• A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma#911528ClinicalTrials.gov
• Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)#836884ClinicalTrials.gov
• Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards#184858ClinicalTrials.gov
• Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment#871534ClinicalTrials.gov
• CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab#208434ClinicalTrials.gov
• PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety#869219ClinicalTrials.gov